Industrial medicinal chemistry insights: neuroscience hit generation at Janssen

Drug Discovery Today

Volumn 22, Issue 10, 2017, Pages 1478-1488

  Tresadern, Gary ^a   Rombouts, Frederik J R ^a   Oehlrich, Daniel ^a   Macdonald, Gregor ^a   Trabanco, Andres A ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BUNGAROTOXIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LIGAND; DRUG;

CHEMOMETRICS; CYCLIZATION; DRUG DELIVERY SYSTEM; DRUG RESEARCH; GENETIC SCREENING; HIGH THROUGHPUT SCREENING; MEDICINAL CHEMISTRY; NEUROSCIENCE; REVIEW; ANIMAL; CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; DRUG DEVELOPMENT; HUMAN; PROCEDURES;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; COMPUTER SIMULATION; DRUG DESIGN; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 85022180845     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2017.05.013     Document Type: Review

References (106)

1. Scannell, J.W., et al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11 (2012), 191–200.
2. Cook, D., et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-Dimensional framework. Nat. Rev. Drug Discov. 13 (2014), 419–431.
3. Munos, B., Lessons from 60 Years of Pharmaceutical Innovation. Nat. Rev. Drug Discov. 8 (2009), 959–968.
4. Paul, S.M., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9 (2010), 203–214.
5. Mullard, A., New drugs cost US$2.6 billion to develop. Nat. Rev. Drug Discov., 13, 2014, 877.
6. Mullard, A., R&D returns continue to fall. Nat. Rev. Drug Discov., 16, 2017, 9.
7. Drews, J., Drug discovery: a historical perspective. Science 17 (2000), 1960–1964.
8. Gordon, E.M., et al. Applications of combinatorial technologies to drug discovery 2. Combinatorial organic synthesis library screening strategies, and future directions. J. Med. Chem. 37 (1994), 1385–1401.
9. Lombardino, J.G., Lowe, J.A., The role of the medicinal chemist in drug discovery - then and now. Nat. Rev. Drug Discov. 3 (2004), 853–862.
10. Lipinski, C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23 (1997), 3–25.
11. Hopkins, A.L., et al. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9 (2004), 430–431.
12. Leeson, P., Chemical beauty contest. Nature 481 (2012), 455–456.
13. Waring, M.J., et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 14 (2015), 475–486.
14. Hann, M.M., Molecular obesity, potency and other addictions in drug discovery. Med. Chem. Commun. 2 (2011), 339–443.
15. Hann, M.M., Oprea, T.I., Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biol. 8 (2004), 255–263.
16. Kola, I., Landis, J., Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 (2004), 711–715.
17. Overington, J.P., et al. How many drug targets are there?. Nat. Rev. Drug Discov. 5 (2006), 993–996.
18. Hay, M., et al. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32 (2014), 40–51.
19. Morgan, P., et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17 (2012), 419–424.
20. Bunnage, M., Getting pharmaceutical R&D back on target. Nat. Chem. Biol. 7 (2011), 335–339.
21. Leeson, P.D., Molecular inflation, attrition and the rule of five. Adv. Drug Deliv. Rev. 101 (2016), 22–33.
22. Eder, J., et al. The discovery of first-in-class drugs: origins and evolution. Nat. Rev. Drug Discov. 13 (2014), 577–587.
23. Bunnage, M.E., et al. Target validation using chemical probes. Nat. Chem. Biol. 9 (2013), 195–199.
24. Hyman, S.E., Back to basics: luring industry back into neuroscience. Nat. Neurosci. 19 (2016), 1383–1384.
25. Abott, A., Novartis to shut down brain research facility. Nature 480 (2011), 161–162.
26. Lafferty-Whyte, K., et al. Trial watch: opportunities and challenges of the 2016 target landscape. Nat. Rev. Drug Discov. 16 (2017), 10–11.
27. Stockwell, B., Exploring biology with small organic molecules. Nature 432 (2004), 846–854.
28. Hoffmann, T., Metternich, R., The future of medicinal chemistry. Angew. Chem. Int. Ed. 51 (2012), 8670–8671.
29. Nicolau, K.C., Advancing the drug discovery and development process. Angew. Chem. 126 (2014), 9280–9292.
30. Ritchie, T.J., Macdonald, S.J.F., The impact of aromatic ring count on compound developability-are too many aromatic rings a liability in drug design?. Drug Discov. Today 14 (2009), 1011–1020.
31. Lovering, F., et al. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 52 (2009), 6752–6756.
32. Oehlrich, D., et al. The evolution of amidine-based brain penetrant BACE1 inhibitors. Bioorg. Med. Chem. Lett. 24 (2014), 2033–2045.
33. Roughley, S.D., Jordan, A.M., The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates. J. Med. Chem. 54 (2011), 3451–3479.
34. Schachter, B., Partnering with the professor. Nat. Biotechnol. 30 (2012), 944–952.
35. Fleury-Bregeot, N., et al. Suzuki-Miyaura cross-coupling of potassium alkoxyethyltrifluoroborates: access to aryl/heteroarylethyloxy motifs. J. Org Chem. 77 (2012), 10399–10408.
36. Fleury-Brègeot, N., et al. Suzuki-Miyaura cross-coupling of potassium dioxolanylethyltrifluoroborate and aryl/heteroaryl chlorides. Org. Lett. 15 (2013), 1536–1539.
37. Verniest, G., et al. Synthesis of aminomethylated 4-fluoropiperidines and 3-fluoropyrrolidines. Org. Biomol. Chem. 8 (2010), 2509–2512.
38. Surmont, R., et al. Synthesis of 4-substituted 3,3-difluoropiperidines. J. Org Chem. 75 (2010), 929–932.
39. Sánchez Casado, M.R., et al. Synthesis of 2,1-borazaroquinolines and 2,1-borazaroisoquinolines from vinylaminopyridines and potassium organotrifluoroborates by microwave-assisted heating. Eur. J. Org. Chem. 2015 (2015), 5221–5229.
40. Rombouts, F.J.R., et al. Benzazaborinines as novel bioisosteric replacements of naphthalene: propranolol as an example. J. Med. Chem. 58 (2015), 9287–9295.
41. Fustero, S., et al. Design, synthesis, and biological evaluation of novel fluorinated ethanolamines. Chemistry 17 (2011), 14772–14784.
42. Sanchez-Rosello, M., et al. Diastereoselective synthesis of 2-phenyl-3-(trifluoromethyl)piperazines as building blocks for drug discovery. J. Org Chem. 79 (2014), 5887–5894.
43. 3-containing 2-pyrrolidones by tandem Michael addition-cyclization: exemplification in the synthesis of amidine class BACE1 inhibitors. Chemistry 21 (2015), 11719–11726.
44. Delgado, O., et al. A practical entry to beta-aryl-beta-alkyl amino alcohols: application to the synthesis of a potent BACE1 Inhibitor. Org. Biomol. Chem. 10 (2012), 6758–6766.
45. Hack, M.D., et al. Library enhancement through the wisdom of crowds. J. Chem. Inf. Model. 51 (2011), 3275–3286.
46. Rabal, O., Oyarzabal, J., Using novel descriptor accounting for ligand-receptor interactions to define and visually explore biologically relevant chemical space. J. Chem. Inf. Model. 52 (2012), 1086–1102.
47. Rombouts, F.J.R., et al., Janssen Pharmaceuticals, Inc., Cellzome Ltd. Preparation of substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-dione derivatives useful for the treatment of Alzheimer's disease. WO 2013171712 A1, 2013.
48. Besnard, J., et al. The Joint European Compound Library: boosting precompetitive research. Drug Discov. Today 20 (2015), 181–186.
49. Karawajczyk, A., et al. The European Lead Factory: a blueprint for public-private partnerships in early drug discovery. Front. Med., 3, 2016, 75.
50. Marsault, E., Peterson, M.L., Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J. Med. Chem. 54 (2011), 1961–2004.
51. Mallinson, J., Collins, I., Macrocycles in new drug discovery. Fut. Med. Chem. 4 (2012), 1409–1438.
52. Jones, L.H., Bunnage, M.E., Applications of chemogenomics library screening in drug discovery. Nat. Rev. Drug Discov. 16 (2017), 285–296.
53. Jacoby, E., et al. Extending kinome coverage by analysis of kinase inhibitor broad profiling data. Drug Discov. Today 20 (2015), 652–658.
54. Martin, L., et al. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res. Rev. 12 (2013), 289–309.
55. Buijnsters, P., et al. Structure-based design of a potent, selective, and brain penetrating PDE2 inhibitor with demonstrated target engagement. ACS Med. Chem. Lett. 5 (2014), 1049–1053.
56. Rombouts, F.J.R., et al. Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as selective, brain penetrant phosphodiesterase 2 (PDE2) inhibitors. ACS Med. Chem. Lett. 6 (2015), 282–286.
57. 3H]R214127: a novel H-A radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol. Pharmacol. 63 (2003), 1082–1093.
58. Lavreysen, H., et al. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology 47 (2004), 961–972.
59. van Westen, G.J.P., et al. Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets. MedChemComm 2 (2011), 16–30.
60. Cortes Ciriano, I., et al. Polypharmacology modelling using proteochemometrics: recent developments and future prospects. MedChemComm 6 (2015), 24–50.
61. Zartler, E., Shapiro, M., Fragment-Based Drug Discovery: a Practical Approach. 2008, Wiley.
62. Erlanson, D.A., Introduction to fragment-based drug discovery. Top. Curr. Chem. 317 (2012), 1–32.
63. Leach, A.R., Hann, M.M., Molecular complexity and fragment-based drug discovery: ten years on. Curr. Opin. Chem. Biol. 15 (2011), 489–496.
64. Keseru, G.M., et al. Design principles for fragment libraries: maximizing the value of learnings from pharma fragment-based drug discovery (FBDD) programs for use in academia. J. Med. Chem. 59 (2016), 8189–8206.
65. Stamford, A., Strickland, C., Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story. Curr. Opin. Chem. Biol. 17 (2013), 320–328.
66. Edwards, P.D., et al. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. J. Med. Chem. 50 (2007), 5912–5925.
67. Rombouts, F.J.R., et al. 1,4-Oxazine β-secretase 1 (BACE1) inhibitors: from hit generation to orally bioavailable brain penetrant leads. J. Med. Chem. 58 (2015), 8216–8235.
68. Rombouts, F.J.R., et al. Fragment binding to β-secretase 1 without catalytic aspartate interactions identified via orthogonal screening approaches. ACS Omega 2 (2017), 685–697.
69. Spurny, R., et al. Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the α7 nicotinic acetylcholine receptor. Proc. Natl. Acad. Sci. 112 (2015), E2543–E2552.
70. Ferruz, N., et al. Multibody cofactor and substrate molecular recognition in the myo-inositol monophosphatase enzyme. Sci. Rep., 6, 2016, 30275.
71. Hu, Y., et al. Recent advances in scaffold hopping. J. Med. Chem. 60 (2017), 1238–1246.
72. Tresadern, G., et al. Scaffold hopping from pyridones to imidazo[1,2-a]pyridines: New positive allosteric modulators of metabotropic glutamate 2 receptor. Bioorg. Med. Chem. Lett. 20 (2010), 175–179.
73. Trabanco, A.A., et al. Imidazo[1,2-a]pyridines: orally active positive allosteric modulators of the metabotropic glutamate 2 receptor. J. Med. Chem. 55 (2012), 2688–2701.
74. Cid, J.M., et al. Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. J. Med. Chem. 55 (2012), 8770–8789.
75. Tresadern, G., et al. QSAR Design of triazolopyridine mGlu2 receptor positive allosteric modulators. J. Mol. Graph. Model 53 (2014), 82–91.
76. Tresadern, G., et al. Rational design and synthesis of aminopiperazinones as beta-secretase (BACE) inhibitors. Bioorg. Med. Chem. Lett. 21 (2011), 7255–7260.
77. Tresadern, G., et al. A comparison of ligand based virtual screening methods and application to corticotropin releasing factor 1 receptor. J. Mol. Graph. Model 27 (2009), 860–870.
78. De Vivo, M., et al. Role of molecular dynamics and related methods in drug discovery. J. Med. Chem. 59 (2016), 4035–4061.
79. Ciordia, M., et al. Application of free energy perturbation for the design of BACE1 inhibitors. J. Chem. Inf. Model. 56 (2016), 1856–1871.
80. Keränen, H., et al. Acylguanidine beta secretase 1 inhibitors: a combined experimental and free energy perturbation study. J. Chem. Theory Comput. 13 (2017), 1439–1453.
81. Ratnam, J., et al. The application of the open pharmacological concepts triple store (open PHACTS) to support drug discovery research. PLoS One, 9, 2014, e115460.
82. International Transporter Consortium, et al. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9 (2010), 215–236.
83. Punitha, A.D., Srivastava, A.K., CNS drug targeting: have we travelled in right path?. J. Drug Target. 21 (2013), 787–800.
84. Seelig, A., et al. A method to determine the ability of drugs to diffuse through the blood- brain barrier. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 68–72.
85. Lai, F., et al. Liposomes for brain delivery. Expert Opin. Drug Deliv. 10 (2013), 1003–1022.
86. Kawikova, I., Askenase, P.W., Diagnostic and therapeutic potentials of exosomes in CNS diseases. Brain Res. 1617 (2015), 63–71.
87. Gao, H., Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm. Sin. B 6 (2016), 268–286.
88. Pavan, B., et al. Progress in drug delivery to the central nervous system by the prodrug approach. Molecules 13 (2008), 1035–1065.
89. Rip, J., et al. Differential receptor-mediated drug targeting to the diseased brain. Expert Opin. Drug Deliv. 6 (2009), 227–237.
90. Burgess, A., et al. Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert Rev. Neurother. 15 (2015), 477–491.
91. Wen, M.M., Olfactory targeting through intranasal delivery of biopharmaceutical drugs to the brain: current development. Discov. Med. 11 (2011), 497–503.
92. Arora, P., et al. Permeability issues in nasal drug delivery. Drug Discov. Today 7 (2002), 967–975.
93. Dhuria, S.V., et al. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 99 (2010), 1654–1673.
94. Ozsoy, Y., et al. Nasal delivery of high molecular weight drugs. Molecules 14 (2009), 3754–3779.
95. Chou, K.-J., Donovan, M.D., The distribution of local anesthetics into the CSF following intranasal administration. Int. J. Pharm. 168 (1998), 137–145.
96. Stevens, J., et al. Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metab. Dispos. 39 (2011), 2275–2282.
97. Westin, U., et al. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur. J. Pharm. Sci. 24 (2005), 565–573.
98. Westin, U.E., et al. Direct nose-to-brain transfer of morphine after nasal administration to rats. Pharm. Res. 23 (2006), 565–572.
99. Hoekman, J.D., Ho, R.J., Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats. Anesth. Analg. 113 (2011), 641–651.
100. Leeson, P.D., Springthorpe, B., The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6 (2007), 881–890.
101. Leeson, P.D., Young, R.J., Molecular property design: does everyone get it?. ACS Med Chem Lett 6 (2015), 722–725.
102. Hansch, C., et al. Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. J. Pharm. Sci. 76 (1987), 663–687.
103. Goodnow, R.A. Jr, et al. DNA-encoded chemistry: enabling the deeper sampling of chemical space. Nat. Rev. Drug Discov. 16 (2017), 131–147.
104. Bartolomé-Nebreda, J.M., et al. Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the mglu5 receptor. J. Med. Chem. 56 (2013), 7243–7259.
105. Macdonald, G.J., Lindsley, C., A unique industrial-academic collaboration towards the next generation of schizophrenia therapeutics. Curr. Top. Med. Chem. 14 (2014), 304–312.
106. Andrews, D.M., et al. Collaborative practices for medicinal chemistry research across big pharma and not-for-profit interface. Drug Discov. Today 19 (2014), 496–501.